CoVLP

CoVLP or Coronavirus-like particles are a type of vaccine technology that is being explored for use in the prevention of COVID-19. CoVLPs are non-infectious and mimic the structure of the SARS-CoV-2 virus, which is the virus that causes COVID-19.

Structure and Function

CoVLPs are made up of the Spike protein of the SARS-CoV-2 virus. This protein is what the virus uses to enter human cells. By presenting this protein to the immune system in a non-infectious form, the body can learn to recognize and fight the virus without the risk of disease.

The Spike protein is assembled into a virus-like particle using a baculovirus expression system. This system uses insect cells to produce the protein, which is then assembled into the CoVLP.

Development and Use

CoVLPs are being developed by several companies as a potential vaccine for COVID-19. One such company, Medicago, has entered Phase 3 clinical trials with their CoVLP vaccine.

The advantage of CoVLPs is that they can be produced quickly and in large quantities. They also do not require any adjuvants, which are substances added to vaccines to enhance the body's immune response.

Safety and Efficacy

As of now, CoVLPs have been shown to be safe and effective in early-stage clinical trials. However, more research is needed to determine their long-term safety and efficacy.

See Also

• COVID-19 vaccine
• Vaccine
• SARS-CoV-2
• Medicago